ABSTRACT
El Dengue es una infección por arbovirus, con baja incidencia de asociación con síntomas neurológicos. Las presentaciones incluyen encefalopatía, síndrome de Guillain-Barré (SGB), debilidad motora aguda, convulsiones, entre otras (1). En el 2018, en Paraguay, se registraron un total de 33.258 casos compatibles con dengue (9), pero no existen datos estadísticos de afectación neurológica. Por lo que consideramos reconocer esta afectación, como marcador de gravedad de la enfermedad. Se relaciona con alta tasa de mortalidad y/o secuelas. A continuación, tres casos masculinos con este padecimiento, de los cuales, recibieron Inmunoglulina con recuperación total en dos de los tres casos, por lo que es muy importante establecer el tratamiento de forma oportuna.
Dengue is an arbovirus infection, with a low incidence of association with neurological symptoms. Presentations include encephalopathy, Guillain-Barré syndrome (GBS), acute motor weakness, seizures, among others (1). In 2018, in Paraguay, a total of 33,258 cases consistent with dengue (9) were registered, but there are no statistical data on involvement neurological. For what, we consider to recognize this affectation, as a marker of severity of the disease. It is related to high mortality rate and / or sequelae. Then, three male cases with this condition, of which, they received Immunoglulin with total recovery in two of the three cases. It is very important to establish the treatment in a timely manner.
ABSTRACT
OBJECTIVE: Few randomized studies have focused on the optimal management of non-intensive care unit patients with type 2 diabetes in Latin America. We compared the safety and efficacy of a basal-bolus regimen with analogues and human insulins in general medicine patients admitted to a University Hospital in Asunción, Paraguay. METHODS: In a prospective, open-label trial, we randomized 134 nonsurgical patients with blood glucose (BG) between 140 and 400 mg/dL to a basal-bolus regimen with glargine once daily and glulisine before meals (n = 66) or Neutral Protamine Hagedorn (NPH) twice daily and regular insulin before meals (n = 68). Major outcomes included differences in daily BG levels and frequency of hypoglycemic events between treatment groups. RESULTS: There were no differences in the mean daily BG (157 ± 37 mg/dL versus 158 ± 44 mg/dL; P = .90) or in the number of BG readings within target <140 mg/dL before meals (76% versus 74%) between the glargine/glulisine and NPH/regular regimens. The mean insulin dose in the glargine/glulisine group was 0.76 ± 0.3 units/kg/day (glargine, 22 ± 9 units/day; glulisine, 31 ± 12 units/day) and was not different compared with NPH/regular group (0.75 ± 0.3 units/kg/day [NPH, 28 ± 12 units/day; regular, 23 ± 9 units/day]). The overall prevalence of hypoglycemia (<70 mg/dL) was similar between patients treated with NPH/regular and glargine/glulisine (38% versus 35%; P = .68), but more patients treated with human insulin had severe (<40 mg/dL) hypoglycemia (7.6% versus 25%; P = .08). There were no differences in length of hospital stay or mortality between groups. CONCLUSION: The basal-bolus regimen with insulin analogues resulted in equivalent glycemic control and frequency of hypoglycemia compared to treatment with human insulin in hospitalized patients with diabetes.
